With the constant progress of clinical trials on innovative drugs such as CDK 4/6 inhibitors, HDAC inhibitors, and PI3K/Akt/mTOR inhibitors, endocrine therapy for hormonal receptor positive advanced breast cancer has entered the era of targeted combination therapy. Facing with various targeted therapeutic drugs, determining the optimal and individualized treatment has become the main focus for clinicians. The updated 2020 version of Chinese Society of Clinical Oncology Breast Cancer guidelines fully take into account the evidence level of evidence-based medicine, changes in drug accessibility, and latest research progress, and propose stratified strategies based on the previous history of endocrine treatment, and recommend endocrine treatment options for hormone receptor-positive advanced breast cancer, providing a guiding basis for the majority of breast cancer medical workers to make reasonable choices in clinical practice.